| Literature DB >> 35815089 |
Narjes Alfuraiji1, Amal Al-Hamami2, Maysaa Ibrahim2, Hassan Khuder Rajab3, Balsam Waleed Hussain4.
Abstract
Uropathogenic Escherichia coli (UPEC) harbors virulence factors responsible for bacterial adhesion and invasion. In addition, the bacterium is accountable for the occurrence of pediatric urinary tract infections globally and is becoming problematic due to the emergence of antimicrobial resistance. The current research investigated UPEC prevalence, virulence characteristics, and antimicrobial resistance in pediatric urinary tract infection (UTI). 200 urine specimens were taken from hospitalized pediatric patients who suffered from UTIs. E. coli was recovered from urine specimens using the microbial culture. Disc diffusion method was used to assess antimicrobial resistance and polymerase chain reaction (PCR) to assess the virulence factors distribution amongst the UPEC bacteria. Seventy-five out of 250 (30.00%) urine samples were positive for the UPEC bacteria. The UPEC prevalence amongst pediatric patients was 25.83% and 33.84%, respectively. UPEC bacteria harbored the maximum resistance toward gentamicin (45.33%), ampicillin (44.00%), and ciprofloxacin (40.00%). Cytotoxic necrotizing factor 1 (Cnf1) (53.33%) and pyelonephritis-associated pil (pap) (42.66%) were the most frequently identified virulence factors amongst the UPEC bacteria. The high prevalence of UPEC isolates harboring antimicrobial resistance and virulence factors suggest that diseases caused by them need more expansive healthcare monitoring with essential demand for novel antimicrobials.Entities:
Keywords: E. coli – Escherichia coli; PCR – Polymerase Chain Reaction; UPEC – Uropathogenic Escherichia coli; UTIs – Urinary Tract Infections; Uropathogenic Escherichia coli; afa – A fimbrial adhesin; antimicrobial resistance; cnf1 – cytotoxic necrotizing factor 1; pap – pyelonephritis-associated pil.; pediatrics; sfa – S fimbriae; virulence factors
Mesh:
Substances:
Year: 2022 PMID: 35815089 PMCID: PMC9262263 DOI: 10.25122/jml-2021-0148
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
PCR procedures used to detect virulence factors [14, 15].
| Genes | Primers (5'-3') | PCR product (bp) | Thermal cycles | Volume (50μL) |
|---|---|---|---|---|
|
| F: GCT GGG CAG CAA ACT GAT AAC TCT C | 750 | PCR buffer 10X: 5 μL | |
| R: CAT CAA GCT GTT TGT TCG TCC GCC G | ||||
|
| F: CTC CGG AGA ACT GGG TGC ATC TTA C | 410 | ||
| R: CGG AGG AGT AAT TAC AAA CCT GGC A | ||||
|
| F: GCA ACA GCA ACG CTG GTT GCA TCA T | 336 | ||
| R: AGA GAG AGC CAC TCT TAT ACG GAC A | ||||
|
| F: AAG ATG GAG TTT CCT ATG CAG GAG | 498 | ||
| R: TGG AGT TTC CTA TGC AGG AG |
UPEC distribution amongst examined urine specimens.
| Urine specimens (Age groups) | N. collected specimens | N. specimens positive for UPEC (%) | |
|---|---|---|---|
|
|
| 25 12 (48.00) | |
|
| 35 | 10 (28.57) | |
|
| 30 | 9 (30.00) | |
|
| 90 | 31 (34.44) | |
|
|
| 30 | 16 (53.33) |
|
| 35 | 14 (40.00) | |
|
| 45 | 14 (31.11) | |
|
| 110 | 44 (40.00) | |
|
| 200 | 75 (37.50) | |
UPEC resistance pattern toward antimicrobial agents.
| Specimens (N. UPEC isolates) | N. isolates harbored resistance toward each antimicrobial (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cef | Cip | Gen | Ofl | Mrp | Amp | Trsul | Nor | Amk | Nal | ||
|
|
| 3 (25.00) | 4 (33.33) | 5 (41.66) | 3 (25.00) | - | 4 (33.33) | 3 (25.00) | 3 (25.00) | 3 (25.00) | 2 (16.66) |
|
| 3 (30.00) | 3 (30) | 4 (40) | 2 (20) | - | 4 (40) | 2 (20) | 2 (20) | 3 (30) | 3 (30) | |
|
| 5 (55.55) | 4 (44.44) | 5 (55.55) | 2 (22/22) | 1 (11/11) | 5 (55.55) | 3 (33/33) | 2 (22/22) | 4 (44.44) | 2 (22/22) | |
|
| 11 (35.48) | 11 (35.48) | 14 (45.16) | 7 (22.58) | 1 (3.22) | 13 (41.93) | 8 (25.80) | 7 (22.58) | 11 (35.48) | 7 (22.58) | |
|
|
| 4 (25.00) | 5 (31.25) | 6 (37.50) | 4 (25.00) | - | 5 (31.25) | 4 (25.00) | 3 (18.75) | 5 (31.25) | 3 (18.75) |
|
| 6 (42.85) | 7 (50.00) | 6 (42.85) | 4 (28.57) | 1 (7.14) | 7 (50.00) | 6 (42.85) | 4 (28.57) | 6 (42.85) | 3 (21.42) | |
|
| 8 (57.14) | 7 (50.00) | 8 (57.14) | 3 (21.42) | 1 (7.14) | 8 (57.14) | 5 (35.71) | 3 (21.42) | 6 (42.85) | 4 (28.57) | |
|
| 18 (40.90) | 19 (43.18) | 20 (45.45) | 11 (25.00) | 2 (4.54) | 20 (45.45) | 15 (34.09) | 10 (22.72) | 17 (38.63) | 10 (22.72) | |
|
| 29 (38.66) | 30 (40.00) | 34 (45.33) | 18 (24.00) | 3 (4.00) | 33 (44.00) | 23 (30.66) | 17 (22.66) | 28 (37.33) | 17 (22.66) | |
Cef – cefotaxime (30 μg/disk); Cip – ciprofloxacin (5 μg/disk); Gen – gentamicin (10 μg/disk); Ofl – ofloxacin (5 μg/disk); Mrp – meropenem (10 μg/disk); Amp – ampicillin (10 μg/disk); Trsu – trimethoprim-sulfamethoxazole (25 μg/disk); Nor – norfloxacin (10 μg/disk); Amk – amikacin (30 μg/disk); Nal – nalidixic acid (30 μg/disk).
UPEC virulence factor profile.
| Specimens (N. UPEC isolates) | N. isolates harbored resistance toward each virulence factor (%) | ||||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
|
| - | 1 (8.33) | 2 (16.66) | 4 (33.33) |
|
| 2 (20) | 1 (10) | 6 (60) | 5 (50) | |
|
| 2 (22.22) | 2 (22.22) | 4 (44.44) | 6 (66.66) | |
|
| 4 (12.90) | 4 (12.90) | 12 (38.70) | 15 (48.38) | |
|
|
| 1 (6.25) | 2 (12.50) | 4 (25.00) | 4 (25.00) |
|
| 2 (14.28) | 3 (21.42) | 6 (42.85) | 8 (57.14) | |
|
| 3 (21.42) | 3 (21.42) | 12 (85.71) | 13 (92.85) | |
|
| 6 (13.63) | 8 (18.18) | 20 (45.45) | 25 (56.81) | |
|
| 10 (13.33) | 12 (16.00) | 32 (42.66) | 40 (53.33) | |